Expanded Access Policy

IO Biotech, Inc. (IO Biotech) is the developer of a novel investigational drug product, IO102‑IO103 Immunotherapeutic Cancer Vaccine. The investigational drug product is being evaluated for the treatment of previously untreated, unresectable or metastatic melanoma regardless of BRAF mutation status in combination with an anti-PD-1 antibody.

For patients who do not qualify for our clinical trials, IO Biotech may open an expanded access program for IO102-IO103 prior to its approval. Currently, we do not have any expanded access programs open for IO102-IO103. We re-evaluate this decision regarding expanded access programs as we complete our Phase 3 trial when new safety and efficacy information that will allow the benefit and risk to be fully assessed becomes available. Please check back for updates on the availability of expanded access or contact info@iobiotech.com with any questions.

Information on IO Biotech’s ongoing trials can be found here.

For further inquiries about IO Biotech’s trials and EA policy, please contact info@iobiotech.com.

IO Biotech, Inc.
Ole Maaløes Vej 3
DK-2200 Copenhagen N